Snowsill et al.; Cost-minimisation analysis of the WID-qEC epigenetic biomarker compared to transvaginal ultrasound for triaging abnormal uterine bleeding. Value in Health, 2026 A newly peer-reviewed cost-minimisation analysis published in Value in Health demonstrates that WID-easy offers a compelling economic and clinical alternative to transvaginal ultrasound (TVUS) as the first-line triage test for patients presenting with abnormal uterine bleeding (AUB) referred to the Ur

Your Quarterly Update on Innovations in Women’s Health Welcome to the July 2025 edition of AGHeadlines , where we share the latest...

When a patient presents with abnormal uterine bleeding, particularly during or after menopause, one of the first concerns clinicians must...

Today, on the International Day of Action for Women’s Health , we stand in recognition and deep gratitude for the tireless work of...

AGHealth now has the support of the NIA to accelerate adoption of WID-easy into the NHS

Preterm birth (PTB) is one of the leading causes of neonatal mortality and morbidity worldwide. Early identification of women and...

Advice from experienced healthcare professionals on finding success with mechanical IOL methods

Preeclampsia is a well known condition, affecting around 6% of all pregnancies. It is typically characterised by proteinuria and high...